Clinical data | |
---|---|
Other names | MT-3995 |
Routes of administration | Oral |
Drug class | Antimineralocorticoid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H17FN2O4S |
Molar mass | 364.39 g·mol−1 |
3D model ( JSmol) | |
| |
|
Apararenone ( INN) (developmental code name MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. [1] [2] [3] It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication. [1] Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (Ki < 50 nM), the receptor for aldosterone. [1] [2] [3] As of 2017, it is in phase II clinical trials. [1]